Downregulation of long noncoding RNA TP73-AS1 expression confers resistance to temozolomide in human glioblastoma cells

Abstract

Glioblastoma multiforme (GBM), the most aggressive primary malignant brain tumor, is resistant to conventional radiotherapies and chemotherapies, including temozolomide (TMZ). Overcoming GBM resistance to the chemotherapeutic agent TMZ poses an important therapeutic problem. This study established an association between the long noncoding RNA TP73-AS1 and TMZ sensitivity regulation in human GBM cells (U87MG). Transcriptomic analysis revealed that TP73-AS1 expression was reduced in TMZ-resistant U87MG^RT100 cells compared to that in parental U87MG cells. Additionally, TP73-AS1 knockdown in parental U87MG cells decreased their sensitivity to TMZ. Overall, these findings suggest that TP73-AS1 functions as a regulator of TMZ sensitivity in GBM cells.

Keywords:

• Drug resistance
• glioblastoma
• long noncoding RNA
• temozolomide
• TP73-AS1

Acknowledgments

We thank Ms. Mika Shindo and Ms. Mana Inada (Tokyo University of Science) for their helpful discussions.

Author contributions

AS conceived and designed the experiments; RO, KT, YO, and AS performed the experiments; RO, KT, YO, and AS analyzed the data; RO and AS wrote the paper.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Data availability statement

The data supporting the findings of this study are available from the corresponding author, AS, upon reasonable request.

Additional information

Funding

The author(s) reported there is no funding associated with the work featured in this article.